Athenex Inc.
| NASDAQ: ATNX | Healthcare / Drug Manufacturers / USA |
| 0.2031 | -0.0620 | -23.39% | Vol 1.85M | 1Y Perf -58.91% |
| May 24th, 2023 16:00 DELAYED |
| BID | 0.2051 | ASK | 0.2052 | ||
| Open | 0.2200 | Previous Close | 0.2031 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 1.25 | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | ★★+ — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | + — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ☆ — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.00 | Earnings Rating | Neutral | |
| Market Cap | 1.76M | Earnings Date | 30th May 2023 | |
| Alpha | -0.07 | Standard Deviation | 0.22 | |
| Beta | 1.35 |
Today's Price Range 0.20160.2571 | 52W Range 0.221023.80 | 5 Year PE Ratio Range -4.90-8.40 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | - | ||
| 3 Months | - | ||
| 6 Months | 0.00% | ||
| 1 Year | -58.91% | ||
| 3 Years | -98.50% | ||
| 5 Years | -98.46% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -73.79 | |||
ROE last 12 Months | -226.22 | |||
ROA (5Y Avg) | -31.68 | |||
ROA last 12 Months | -62.54 | |||
ROC (5Y Avg) | -76.96 | |||
ROC last 12 Months | -85.62 | |||
Return on invested Capital Q | -24.32 | |||
Return on invested Capital Y | -38.80 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 3.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.10 | ||||
| 1.14 | ||||
| 0.30 | ||||
| - | ||||
| -0.50 | ||||
| -0.84 | ||||
| -0.60 | ||||
| 0.16 | ||||
| 34.70M | ||||
| Forward PE | -0.11 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 1.50 | ||||
| 0.51 | ||||
| 1.72 | ||||
| -7.90 | ||||
| Leverage Ratio | 9.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 21.40 | ||||
| -128.90 | ||||
| -125.70 | ||||
| -220.50 | ||||
| -74.51 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 94.19M | ||||
| 0.60 | ||||
| 13.16 | ||||
| 37.94 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | -1.00 | -3.38 | -238.00 |
| Q03 2022 | -3.20 | -2.80 | 12.50 |
| Q02 2022 | -2.60 | -4.60 | -76.92 |
| Q01 2022 | -3.20 | -4.80 | -50.00 |
| Q04 2021 | -0.80 | -5.80 | -625.00 |
| Q03 2021 | -8.20 | -6.60 | 19.51 |
| Q02 2021 | -0.41 | -0.33 | 19.51 |
| Q01 2021 | -0.37 | -0.27 | 27.03 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2023 QR | -2.35 | 58.77 | Positive |
| 6/2023 QR | -0.32 | - | - |
| 12/2023 FY | -3.09 | - | - |
| 12/2024 FY | -1.71 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.85M |
| Shares Outstanding | 433 |
| Shares Float | 7.61M |
| Trades Count | 3.31K |
| Dollar Volume | 413.94K |
| Avg. Volume | 499.58K |
| Avg. Weekly Volume | 797.54K |
| Avg. Monthly Volume | 467.49K |
| Avg. Quarterly Volume | 233.72K |
Athenex Inc. (NASDAQ: ATNX) stock closed at 0.2031 per share at the end of the most recent trading day (a -23.39% change compared to the prior day closing price) with a volume of 1.67M shares and market capitalization of 87.94K. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 581 people. Athenex Inc. CEO is Johnson Y.N. Lau.
The one-year performance of Athenex Inc. stock is -58.91%, while year-to-date (YTD) performance is 37.69%. ATNX stock has a five-year performance of -98.46%. Its 52-week range is between 0.221 and 23.8, which gives ATNX stock a 52-week price range ratio of %
Athenex Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 1.14, a price-to-sale (PS) ratio of 0.30, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -62.54%, a ROC of -85.62% and a ROE of -226.22%. The company’s profit margin is -74.51%, its EBITDA margin is -125.70%, and its revenue ttm is $94.19 Million , which makes it $0.60 revenue per share.
Of the last four earnings reports from Athenex Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Athenex Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Athenex Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Athenex Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Athenex Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Athenex Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 32.73, ATR14 : 0.14, CCI20 : -100.62, Chaikin Money Flow : -0.09, MACD : -0.29, Money Flow Index : 9.16, ROC : -84.84, RSI : 18.34, STOCH (14,3) : 0.12, STOCH RSI : 0.00, UO : 36.09, Williams %R : -99.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Athenex Inc. in the last 12-months were: Annoni Joe (Sold 0 shares of value $0 ), Joe Annoni (Option Excercise at a value of $0)
Athenex Inc.
Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company's operating segment includes the Oncology Innovation Platform; Global Supply Chain Platform and Commercial Platform. It generates maximum revenue from the Commercial Platform segment. Commercial Platform segment includes APD, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. Geographically, it derives a majority of revenue from the United States and also has a presence in Spain; Austria; India; China; the United Kingdom and Other foreign countries.
CEO: Johnson Y.N. Lau
Telephone: +1 716 427-2950
Address: 1001 Main Street, Buffalo 14203, NY, US
Number of employees: 581
